RA Capital Healthcare Fund LP 4

What Happened

• RA Capital Management, L.P. (a reported 10% owner) purchased shares of Artiva Biotherapeutics (ARTV). The filing shows 31,000 shares bought on 2026-06-25 at a weighted-average price of $8.88 ($275,280) and 1,876 shares bought on 2026-06-26 at $8.98 ($16,846), for a combined purchase of 32,876 shares costing approximately $292,126. These transactions are coded "P" (purchase), i.e., outright buys — purchases are generally taken as more informative than routine sales.

Key Details

• Transaction dates and prices:
  • 2026-06-25: 31,000 shares at $8.88 (weighted avg) — $275,280.
  • 2026-06-26: 1,876 shares at $8.98 — $16,846.
• Total shares bought: 32,876; total cash outlay ≈ $292,126.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Notable footnotes:
  • F1 notes the $8.88 price is a weighted average for purchases ranging $8.62–$8.98.
  • F2 clarifies RA Capital Management, L.P. is the adviser to several funds/accounts and that the adviser and related parties disclaim beneficial ownership except to the extent of pecuniary interest.
  • Other footnotes (F3–F7) indicate holdings may be held directly by specific funds/accounts.
  • The filing remarks that Laura Stoppel, a Principal of the Adviser, serves on Artiva’s board.
• Filing timeliness: Form 4 filed 2026-06-29 reporting the 6/25–6/26 trades; no late-filing indication in the provided excerpt.

Context

• RA Capital is an institutional investment manager (a 10% owner) rather than an individual executive; the adviser structure and disclaimers in the filing mean reported trades reflect the adviser or its funds/accounts, not necessarily personal trades by named individuals.
• These were purchases (not option exercises, gifts, or awards), which some investors view as a mild bullish signal because an institutional holder increased its position.